How to Get Praluent (Alirocumab) in Arkansas

What Praluent Is and Why Arkansas Patients Need It

Alirocumab (brand name Praluent) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. By blocking PCSK9, alirocumab allows LDL receptors to recycle back to the hepatocyte surface, pulling more LDL-cholesterol out of circulation. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering on top of diet and maximally tolerated statin therapy [1].

Arkansas carries a meaningful cardiovascular burden. The CDC reports that age-adjusted heart disease mortality in Arkansas ranks among the top ten states nationally, with rates approximately 30% above the national median [2]. For patients who cannot reach LDL-C targets on statins alone, alirocumab offers a clinically proven alternative.

In ODYSSEY OUTCOMES (N=18,924), alirocumab 75 to 150 mg every two weeks reduced major adverse cardiovascular events (MACE) by 15% compared with placebo in patients who had experienced an acute coronary syndrome in the prior 1 to 12 months (hazard ratio 0.85 to 95% CI 0.78 to 0.93, P<0.001) [3]. Mean LDL-C fell from 87 mg/dL at baseline to 48 mg/dL at 4 months in the alirocumab group. Those results form the clinical rationale that payers and physicians in Arkansas use when evaluating whether a patient qualifies.

The 2022 ACC/AHA Guideline on Cardiovascular Risk Management states: "In patients with very high-risk ASCVD who are on maximally tolerated statin therapy and ezetimibe with LDL-C remaining at or above 70 mg/dL, it is reasonable to add a PCSK9 inhibitor" [4]. Arkansas prescribers apply that exact language when writing prior authorization letters.

Who Can Prescribe Praluent in Arkansas

Any licensed prescriber in Arkansas with authority to prescribe Schedule and non-scheduled legend drugs may write a Praluent prescription. That includes MDs, DOs, NPs (nurse practitioners operating under a collaborative practice agreement or independent practice authority per Arkansas Code 17-87-310), and PAs (physician assistants per Arkansas Code 17-105-101 et seq.) [5].

Cardiologists and lipidologists are the most common prescribers because Praluent's prior authorization criteria typically require documented statin intolerance or insufficient LDL-C response. Primary care physicians also prescribe it, particularly in rural Arkansas counties where specialist access is limited. Telehealth providers licensed in Arkansas carry the same prescribing authority as in-person clinicians for non-controlled medications, provided a valid patient-provider relationship is established [6].

One practical note: specialty pharmacies often require a prescriber DEA number on file even for non-controlled drugs, so ensure your provider has completed specialty pharmacy enrollment before the prescription is transmitted.

How to Get a Praluent Prescription in Arkansas: Step by Step

Getting alirocumab requires completing several sequential steps. Missing any one can delay the first injection by weeks, so understanding the sequence reduces friction.

Step 1. Establish a clinical relationship. Schedule an appointment with a cardiologist, lipidologist, or primary care physician in Arkansas, or connect with a telehealth provider licensed in the state. The visit must include a review of your cardiovascular history, current medications, and lipid panel results. Telehealth appointments typically run 20 to 40 minutes and can result in a same-day prescription if labs are current.

Step 2. Obtain qualifying labs. Your provider needs a fasting lipid panel drawn within the past 90 days. Many Arkansas offices require a fasting lipid panel, a comprehensive metabolic panel (CMP), and a thyroid-stimulating hormone (TSH) level to rule out secondary hypercholesterolemia before initiating a PCSK9 inhibitor. LabCorp and Quest both operate draw sites in Little Rock, Fort Smith, Fayetteville, Jonesboro, and Pine Bluff, and most results return within 24 to 48 hours.

Step 3. Document statin history. Prior authorization for alirocumab in Arkansas almost universally requires evidence that the patient has tried at least one high-intensity statin (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg) and either (a) failed to reach the LDL-C target or (b) experienced documented statin-associated muscle symptoms (SAMS) that required discontinuation. Keep pharmacy fill records or a letter from a previous prescriber confirming statin intolerance.

Step 4. Submit a prior authorization request. The prescriber's office initiates a PA through the patient's insurance plan. Commercial plans in Arkansas (Blue Cross and Blue Shield of Arkansas, QualChoice, Ambetter, Arkansas Health and Wellness) typically require LDL-C values, statin trial documentation, and the specific ICD-10 code (E78.01 for HeFH or I25.10 for ASCVD) [7]. Turnaround is typically 3 to 7 business days; peer-to-peer reviews can accelerate a denied case.

Step 5. Enroll in Sanofi's specialty pharmacy channel. Praluent is distributed through a network of specialty pharmacies including CVS Specialty, Walgreens Specialty, and Accredo. The prescriber transmits the prescription electronically or by fax. The specialty pharmacy contacts the patient within 1 to 2 business days to verify insurance, shipping address, and injection training preferences.

Step 6. Receive and store the medication. Alirocumab ships refrigerated (36 to 46°F) via 2-day cold-chain shipping. Patients in rural Arkansas should confirm a delivery address where someone will be present to receive the package. Praluent may be stored at room temperature (up to 77°F) for up to 30 days in the original carton, which provides flexibility for patients without immediate refrigerator access.

Telehealth Access to Praluent in Arkansas

Arkansas permits telehealth prescribing of non-controlled medications following the establishment of a valid provider-patient relationship. Arkansas Code 23-79-1602 and the Arkansas State Medical Board's telehealth policy do not require an initial in-person encounter before a prescription can be issued, provided the provider conducts an appropriate evaluation using real-time audio-visual technology [6].

HealthRX operates in Arkansas and can evaluate patients for alirocumab eligibility through a structured cardiovascular risk assessment. The process begins with an online intake form capturing lipid history, current medications, cardiovascular events, and family history. A board-certified clinician reviews the intake and conducts a live video visit. If the patient qualifies clinically, the prescriber submits the PA and routes the prescription to the patient's preferred specialty pharmacy the same day.

Telehealth prescribing does not reduce the PA burden. Every insurer still requires the same clinical documentation. What telehealth removes is the barrier of traveling to a specialist in Little Rock or another metro area, which is particularly meaningful for the approximately 600,000 Arkansans living in rural counties more than 30 miles from a cardiologist [2].

Labs Required Before Praluent in Arkansas

The lab workup is straightforward. Most Arkansas prescribers order the following before initiating alirocumab:

A fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C) is the cornerstone. LDL-C should be measured while the patient is on their current maximally tolerated statin, not after stopping it, because the PA requires documentation of on-treatment LDL-C. A CMP screens for hepatic or renal contraindications. TSH rules out hypothyroidism as a correctable cause of high LDL-C. Some cardiologists also add a lipoprotein(a) level, given that Lp(a) elevation is an independent ASCVD risk factor and may strengthen the PA argument.

Baseline creatine kinase (CK) is optional but reasonable in patients with a history of myopathy. Alirocumab itself does not cause myopathy, but the baseline CK can be useful if a statin is being co-prescribed or continued at a lower dose.

Results from any CLIA-certified laboratory in Arkansas are acceptable for PA submission. Direct-to-patient lab orders through HealthRX can be fulfilled at Quest or LabCorp draw sites statewide.

Prior Authorization Requirements in Arkansas

Prior authorization is the single largest source of delay for Arkansas patients seeking Praluent. Understanding what each payer requires lets you submit a complete PA package the first time, avoiding the back-and-forth that can extend timelines by 2 to 4 weeks.

Commercial plans (BCBS Arkansas, QualChoice, Ambetter). These plans follow criteria aligned with the ACC/AHA guidelines. Standard documentation includes: (1) ICD-10 diagnosis of HeFH (E78.00 or E78.01) or ASCVD (I25.10); (2) current fasting LDL-C value on maximally tolerated statin; (3) names, doses, and durations of at least one high-intensity statin trial; (4) documentation of statin intolerance if applicable; and (5) ezetimibe trial or documented contraindication [7]. Some plans also ask for a Simon Broome or Dutch Lipid Clinic Network score to confirm HeFH diagnosis.

Arkansas Medicaid (Arkansas Works, traditional Medicaid). Coverage for PCSK9 inhibitors under Arkansas Medicaid is limited. The program covers alirocumab for adults with documented HeFH or established ASCVD who have tried and failed two statins at maximally tolerated doses AND have added ezetimibe, and whose LDL-C remains at or above 100 mg/dL on that combination. Prior authorization requests must be submitted by the prescribing physician and renewed annually [8]. The Arkansas DHS Preferred Drug List (PDL) places alirocumab in a non-preferred tier requiring PA; evolocumab (Repatha) is subject to the same criteria.

Step therapy. Several Arkansas commercial plans require step therapy documentation showing the patient has trialed a generic statin (simvastatin, atorvastatin, rosuvastatin) before approving a branded PCSK9 inhibitor. If your plan has a step therapy requirement, your prescriber's PA letter should explicitly address each step.

The American Heart Association's 2021 policy statement on step therapy reads: "Step therapy protocols should not delay access to clinically appropriate therapies for patients at high cardiovascular risk" [9]. Prescribers can cite that statement in PA appeal letters when step therapy requirements conflict with guideline-directed management.

Cost and Copay Assistance for Arkansas Patients

Praluent's list price is approximately $5,850 per month. Very few patients pay that figure.

Sanofi Praluent copay card. Commercially insured patients who are not enrolled in a government program (Medicare, Medicaid, CHIP) may pay as little as $0 per month through Sanofi's copay program. Eligibility is confirmed online at the time of pharmacy enrollment. The card covers the gap between insurance payment and the patient's cost-share up to a defined annual cap.

Sanofi Patient Assistance Program (PAP). Uninsured or underinsured patients with household income at or below 400% of the federal poverty level may qualify for free medication through Sanofi's PAP. Applications are submitted by the prescriber's office or the patient directly through Sanofi's website.

Medicare Part D. With the 2025 Medicare Part D out-of-pocket cap of $2,000 under the Inflation Reduction Act, the annual cost for Medicare beneficiaries who pass the PA threshold is now bounded. PCSK9 inhibitors are typically placed in Tier 4 or 5 on Part D formularies, meaning some plans will charge 25 to 33% coinsurance until the $2,000 cap is reached.

340B hospitals in Arkansas. Patients receiving care at a 340B-covered entity, such as the University of Arkansas for Medical Sciences (UAMS) outpatient clinic, may access alirocumab at substantially reduced cost through the 340B drug pricing program.

503A Compounding Pharmacies in Arkansas

503A pharmacies in Arkansas may compound alirocumab for individual patients with a valid prescription, following USP <797> sterile compounding standards. This pathway exists primarily for patients who are commercially uninsured and do not qualify for manufacturer assistance, or those with documented allergies to excipients in the branded formulation.

Compounded alirocumab is not FDA-approved, and the clinical data supporting its safety and efficacy come entirely from studies of the branded product. Prescribers in Arkansas who route patients to 503A compounders should document the medical necessity and ensure the pharmacy holds a current Arkansas State Board of Pharmacy 503A license [10]. The Arkansas Board of Pharmacy publishes a searchable licensee database at asbp.arkansas.gov.

Patients should confirm that the compounding pharmacy uses validated analytical testing for potency and sterility. The American Society of Health-System Pharmacists recommends that sterile compounded biologics be tested by an ISO-accredited third-party lab before dispensing.

Transferring an Existing Praluent Prescription to Arkansas

If you are moving to Arkansas or establishing residency while already on alirocumab, the transfer process is straightforward for specialty pharmacy prescriptions.

Contact your current specialty pharmacy and request a transfer to an Arkansas-licensed specialty pharmacy or to the same national specialty pharmacy chain that operates in Arkansas. Because Praluent is a refillable specialty medication, the receiving pharmacy can contact the prescriber of record for a new Arkansas-valid prescription if required by state law. Arkansas does not prohibit specialty pharmacies licensed in other states from shipping to Arkansas residents, provided the dispensing pharmacy holds a valid Arkansas non-resident pharmacy permit from the State Board of Pharmacy [10].

If your previous prescriber was in another state, you will need a new prescription from an Arkansas-licensed provider before the Arkansas specialty pharmacy can dispense. A telehealth visit with an Arkansas-licensed clinician covers this requirement efficiently. Bring your most recent LDL-C lab results and a medication history to the visit to avoid repeating labs unnecessarily.

Monitoring and Follow-Up After Starting Praluent

Alirocumab does not require routine liver function monitoring under the FDA label, unlike some older lipid-lowering agents [1]. Still, most Arkansas cardiologists check a fasting lipid panel 4 to 8 weeks after the first injection to confirm LDL-C response and to support PA renewal documentation.

The target LDL-C for very-high-risk ASCVD patients is <55 mg/dL per the 2022 ACC/AHA guidelines, and <70 mg/dL for high-risk patients [4]. If LDL-C has not fallen by at least 40% from baseline at the 8-week check, confirm that injections are being administered correctly and that the auto-injector has been stored at the correct temperature.

Injection site reactions occur in approximately 7.2% of alirocumab-treated patients in clinical trials versus 5.1% on placebo, most commonly mild erythema or bruising that resolves without intervention [3]. Nasopharyngitis and urinary tract infections were slightly more common in the alirocumab group in ODYSSEY OUTCOMES, though the absolute difference was small (4.8% vs. 4.5% for nasopharyngitis).

PA renewals in Arkansas are typically required annually. Schedule a follow-up lipid panel 4 weeks before the PA expiration date so results are available when the prescriber submits the renewal request.